Bluebird Bio vs. Sloan-Kettering: Gene Therapy Patent Dispute Ends in Voluntary Dismissal
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Bluebird bio, Inc. v. Sloan-Kettering Institute for Cancer Research |
| Case Number | 24-2010 (Fed. Cir.) |
| Court | Federal Circuit, Appeal from D.C. |
| Duration | June 2024 – Aug 2025 1 year 1 month |
| Outcome | Voluntarily Dismissed – Mutual Costs |
| Patents at Issue | |
| Accused Products | Vector encoding human globin gene and use thereof in treatment of hemoglobinopathies |
Case Overview
The Parties
⚖️ Plaintiff
Clinical-stage biotechnology company headquartered in Somerville, Massachusetts, specializing in gene therapies for severe genetic diseases and cancer. Known for therapies like Zynteglo and Lyfgenia.
🛡️ Defendant
The research arm of Memorial Sloan Kettering Cancer Center in New York, one of the world’s foremost cancer research institutions with an extensive portfolio of foundational gene therapy patents.
Patents at Issue
This case centered on a critical gene therapy patent covering foundational technology for treating blood disorders:
- • US7541179B2 — A vector encoding a human globin gene and its application in treating hemoglobinopathies
Developing gene therapies or similar products?
Check if your gene therapy construct or methodology might infringe this or related patents.
The Verdict & Legal Analysis
Outcome
The proceeding was **dismissed under Fed. R. App. P. 42(b)** upon agreement of the parties, with each side bearing its own costs. No damages award, royalty determination, or injunctive relief was issued. The specific terms of any underlying settlement or licensing agreement were not disclosed in the public record.
Key Legal Issues
The case was grounded in a **patentability challenge** — categorized formally as an invalidity/cancellation action. While specific legal theories were not detailed, invalidity challenges in gene therapy patent cases commonly invoke: Obviousness (35 U.S.C. § 103), Written Description/Enablement (35 U.S.C. § 112), and Anticipation (35 U.S.C. § 102).
Drafting gene therapy patents?
Learn from this case. Use AI to draft stronger claims for biotechnology inventions.
Power Your Gene Therapy IP Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis for Gene Therapy
This case highlights critical IP risks in the rapidly evolving gene therapy sector. Choose your next step:
📋 Understand Gene Therapy IP Landscape
Learn about the specific risks and implications from this litigation.
- View related patents in the gene therapy space
- See which research institutions are active patent holders
- Understand claim construction patterns for biotechnology
🔍 Check My Gene Therapy Product’s Risk
Run a comprehensive FTO analysis for your own gene therapy product or platform.
- Input your construct description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Foundational gene therapy vector constructs
US7541179B2 Patent Family
Critical to monitor for continuations and reexaminations
Strategic Resolution
Voluntary dismissal suggests negotiated settlement
✅ Key Takeaways for Gene Therapy IP
For Patent Attorneys & Litigators
Voluntary Federal Circuit dismissals under Rule 42(b) with mutual cost-bearing often signal confidential commercial resolution.
Search related case law →Invalidity/cancellation actions against foundational biotech patents face high evidentiary bars; early FTO and IPR strategy is preferable.
Explore precedents →For R&D Teams
Gene therapy programs using lentiviral vectors for hemoglobinopathy applications should undergo rigorous FTO review against foundational academic IP.
Start FTO analysis for my product →Settlement at the appellate stage, while costly in legal fees, can preserve commercial program timelines better than protracted Federal Circuit proceedings.
Try AI patent drafting →Ready to Strengthen Your Gene Therapy Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes in biotech.